Patient Perception of the Burden of Weight Gain and Blood Pressure Increase among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs

Journal of Clinical Rheumatology

Volumn 9, Issue 6, 2003, Pages 344-353

  Wolfe, Frederick ^a,c   Michaud, Kaleb ^a   Zhao, Sean Z ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b PFIZER INC   (United States)

^c ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

Celecoxib; COX 2; Edema; Hypertension; NSAID; Rofecoxib; Weight gain

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; IBUPROFEN; INFLIXIMAB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ROFECOXIB;

ADULT; ARTHRITIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DISABILITY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; EDEMA; FEMALE; HEALTH STATUS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERCEPTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0347386408     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000099744.85700.50     Document Type: Article

References (34)

1. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase·2·selective inhibition. Am J Med 1999;107:65S-70S.
2. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991;90:S42-S47.
3. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107:628-35.
4. Bulpitt CJ. Pharmaco-epidemiological considerations in patients with arthritis and vascular disease of the kidney. Scand J Rheumatol Suppl. 1986;62:4-13.
5. Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1983;143:1130-4.
6. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA. 1990;264:471-5.
7. Murray MD, Brater DC. Adverse effects on nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med. 1990;112:559-60.
8. Stillman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity: should we be concerned. Arch Intern Med. 1990;150:268-70.
9. Unsworth J, Sturman S, Lunec J, Blake DR. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1987;46:233-6.
10. Appel GB. COX-2 inhibitors and the kidney. Clin Exp Rheumatol. 2001;19(Suppl 25):S37-S40.
11. Sundy JS. Cox-2 inhibitors in rheumatoid arthritis. Curr Rheumatol Rep. 2001;3:86-91.
12. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib. Clin Ther. 2001;23:1478-91.
13. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study [see comments]. JAMA. 2000;284:1247-55.
14. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465-70.
15. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
16. Whelton A, White WB, Bello AE, et al. Effects of Celecoxib and Rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
17. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2.
18. Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol. 2002;29:467-73.
19. Wolfe F, Flowers N, Burke TA, et al. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 2002;29:1015-22.
20. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice. Arthritis Rheum (suppl). 1998;41:S132.
21. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789-93.
22. Fries JF, Spitz PW, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
23. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum. 1995;38:795-8.
24. Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. Arthritis Rheum. 2001;44:53-60.
25. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford). 2000;39:321-327.
26. Wolfe F. The importance of gastrointestinal (GI) symptom severity in rheumatoid and osteoarthritis: Symptom rates and risk for GI hospitalization. J Rheumatol. 2000;27:1661-7.
27. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol. 2000;27:1373-8.
28. Stata Corporation. Stata Statistical Software: Release 7.0. 2001.
29. Konhoff M, Grone HJ, Klein T. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997;272:F460-F468.
30. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-10.
31. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76-84.
32. VIGOR. Vioxx VIGOR Gastrointestinal Outcomes Study (VIGOR). Food and Drug Administration web site 2002; http://www.FDA.gov/ohrms/dockets/ac/htm.
33. CLASS. FDA Advisory committe briefing information. Food and Drug Administration web site 2002; http://www.fda.ohrms/dockets/ac/htm.
34. Zhao SZ, Burke TA, von Allmen H. Cost of heart failure among hypertensive users of traditional NSAIDs and COX-2 specific inhibitors. Am J Manag Care 2002.